Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression

International Journal of Developmental Neuroscience

Volumn 17, Issue 5-6, 1999, Pages 473-481

  Sandström, Maria ^a   Johansson, Mikael ^a   Sandström, Jan ^a   Bergenheim, A Tommy ^a   Henriksson, Roger ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Angiogenesis; Glioma; Migration; PAI 1; tPA; uPA; VEGF

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CANCER INVASION; CELL CULTURE; CELL INVASION; CHOROID PLEXUS; CONTROLLED STUDY; EPENDYMA; GLIOMA; GLIOMA CELL; IN SITU HYBRIDIZATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ZYMOGRAPHY;

ANIMALS; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; LYMPHOKINES; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032863927     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-5748(99)00050-7     Document Type: Article

References (40)

1. Bergenheim A.T., Elfverson J., Gunnarsson P.-O., Edman K., Hartman M., Henriksson R. Cytotoxic effect and uptake of estramustine in a rat glioma model. Int. J. Oncol. 5:1994;293-299.
2. Bindal A.K., Hammoud M., Shi W.M., Wu S.Z., Sawaya R., Rao J.S. Prognostic significance of proteolytic enzymes in human brain tumors. J. Neurooncol. 22:1994;101-110.
3. Bykowska K., Rijken D.C., Collen D. Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture. Thromb. Haemost. 46:1981;642-644.
4. Crowley C.W., Cohen R.L., Lucas B.K., Liu G., Shuman M.A., Levinson A.D. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. 90:1993;5021-5025.
5. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:1992;989-991.
6. Duffy M.J. Proteases as prognostic markers in cancer. Clin. Cancer Res. 2:1996;613-618.
7. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am. J. Pathol. 146:1995;1029-1039.
8. Foekens J.A., Buessecker F., Peters H.A., Kranick U., Van Putten W.L.J., Look M.P., Klijn J.G.M., Kramer M.D. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res. 55:1995;1423-1427.
9. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6.
10. Gladson C.L., Pijuan-Thompson V., Olman M.A., Gillespie G.Y., Yacoub I.Z. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am. J. Pathol. 146:1995;1150-1160.
11. Goldberg W.J., Levine K.V., Tadvalkar G., Laws E.R. Jr, Bernstein J.J. Mechanisms of C6 glioma cell and fetal astrocyte migration into hydrated collagen 1 gels. Brain Res. 581:(1):1992;81-90.
12. Gross J.L., Behrens D.L., Mullins D.E., Kornblith P.L., Dexter D.L. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res. 48:1988;291-296.
13. Grugel S., Finkenzeller G., Weindel K., Barleon B., Marme D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 270:1995;25915-25919.
14. Hsu D.W., Efird J.T., Hedley-Whyte E.T. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am. J. Pathol. 147:1995;114-123.
15. Ijichi A., Sakuma S., Tofilon P.J. Hypoxia-induced vascular endothelial growth factor expression in normal rat astrocyte cultures. Glia. 14:1995;87-93.
16. Jankun J., Keck R.W., Skrzypczak-Jankun E., Swiercz R. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res. 57:1997;559-563.
17. Kinder D.H., Berger M.S., Mueller B.A., Silber J.R. Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain. Oncol. Res. 5:1993;409-414.
18. Kolch W., Martiny-Baron G., Kieser A., Marme D. Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res. Treatment. 36:1995;139-155.
19. Kono S., Shi D.M., Rao J.S., Bruner J.M., Sawaya R. Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J. Neuropathol. Exp. Neur. 53:1994;256-262.
20. Landau B.J., Kwaan H.C., Verrusio E.N., Brem S.S. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res. 54:1994;1105-1108.
21. Mandriota S.J., Graxiano S., Vassalli J.D., Ferrara N., Wasi S., Mazzieri R., Mignatti P., Pepper M.S. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J. Biol. Chem. 270:1995;9709-9716.
22. Mandriota S.J., Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J. Cell Sci. 110:1997;2293-2302.
23. Mohanam S., Sawaya R., McCutcheon I., Ali-Osman F., Boyd D., Rao J.S. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 53:1993;4143-4147.
24. Nakata S., Ito K., Fujimori M., Shingu K., Kajikawa S., Adachi W., Matsuyama I., Tsuchiya S., Kuwano M., Amano J. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int. J. Cancer. 79:1998;179-186.
25. Ossowski L., Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 35:1983;611-619.
26. Pepper M.S., Ferrara N., Orci L., Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181:1991;902-906.
27. Plate K.H., Warnke P.C. Vascular endothelial growth factor. J. Neurooncol. 35:1997;365-372.
28. Rao J.S., Rayford A., Yamamoto M., Ang K.K., Tofilon P., Sawaya R. Modulation of fibrinolysis by ionizing radiation. J. Neurooncol. 22:1994;161-171.
29. Reich R., Thompson E.W., Iwamoto Y., Martin G.R., Deason J.R., Fuller G.C., Miskin R. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res. 48:1988;3307-3312.
30. Salonen E.-M., Gombau L., Engvall E., Schleef R.R. Human glioma U-251 cells contain type 1 plasminogen activator inhibitor in a rapidly releasable form. F.E.B.S. Lett. 393:1996;216-220.
31. Sappino A.P., Huarte J., Vassalli J.D., Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J. Clin. Invest. 87:1991;962-970.
32. Sitrin R.G., Gyetko M.R., Kole K.L., McKeever P., Varani J. Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines. Cancer Res. 50:1990;4957-4961.
33. 3 binding to vitronectin. Nature. 383:1996;441-443.
34. Terman B.I., Dougher Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187:1992;1579-1586.
35. Umeda T., Eguchi Y., Okino K., Kodama M., Hattori T. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J. Pathol. 183:1997;388-397.
36. van Hinsbergh V.W., Koolwijk P., Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. EXS. 79:1997;391-411.
37. Weindel K., Moringlane J.R., Marmé D., Weich H.A. Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? Neurosurgery. 35:1994;439-449.
38. Wollenberg B., Jan N.V., Jund R., Chaubal S., Untch M. Urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor-1: new functional risk factors in head and neck squamous cell cancer. Oncol. Rep. 4:1997;853-855.
39. Yamamoto M., Sawaya R., Mohanam S., Bindal A.K., Bruner J.M., Oka K., Rao V.H., Tomonaga M., Nicolson G.L., Rao J.S. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res. 54:1994;3656-3661.
40. Yoshida D., Piepmeier J.M., Bergenheim T., Henriksson R., Teramoto A. Suppression of matrix metalloproteinase-2-mediated cell invasion in U87MG, human glioma cells by anti-microtubule agent: in vitro study. Br. J. Cancer. 77:(1):1998;21-25.